Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis

REFERENCES

1. 1.↵
   1. Jennette JC,
   2. Falk RJ,
   3. Bacon PA,
   4. Basu N,
   5. Cid MC,
   6. Ferrario F,
   7. et al.

   2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Grayson PC,
   2. Alehashemi S,
   3. Bagheri AA,
   4. Civelek AC,
   5. Cupps TR,
   6. Kaplan MJ,
   7. et al.

   (18)F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol 2018;70:439–49.

   OpenUrl
3. 3.↵
   1. Direskeneli H,
   2. Aydin SZ,
   3. Merkel PA

   . Assessment of disease activity and progression in Takayasu’s arteritis. Clin Exp Rheumatol 2011;1 Suppl 64:S86–91.

   OpenUrl
4. 4.↵
   1. Aydin SZ,
   2. Direskeneli H,
   3. Merkel PA;
   4. International Delphi on Disease Activity Assessment in Large-vessel Vasculitis

   . Assessment of disease activity in large-vessel vasculitis: results of an international Delphi exercise. J Rheumatol 2017;44:1928–32.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Kerr GS,
   2. Hallahan CW,
   3. Giordano J,
   4. Leavitt RY,
   5. Fauci AS,
   6. Rottem M,
   7. et al.

   Takayasu arteritis. Ann Int Med 1994;120:919–29.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Direskeneli H,
   2. Aydin SZ,
   3. Kermani TA,
   4. Matteson EL,
   5. Boers M,
   6. Herlyn K,
   7. et al.

   Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011;38:1471–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Salvarani C,
   2. Cantini F,
   3. Boiardi L,
   4. Hunder GG

   . Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol 2003;6 Suppl 32:S23–8.

   OpenUrl
8. 8.↵
   1. Salvarani C,
   2. Hunder GG

   . Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001;45:140–5.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kermani TA,
   2. Warrington KJ,
   3. Cuthbertson D,
   4. Carette S,
   5. Hoffman GS,
   6. Khalidi NA,
   7. et al;
   8. Vasculitis Clinical Research Consortium

   . Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol 2015;42:1213–7.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Berger CT,
    2. Sommer G,
    3. Aschwanden M,
    4. Staub D,
    5. Rottenburger C,
    6. Daikeler T

    . The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis. Swiss Med Wkly 2018;148:w14661.

    OpenUrl
11. 11.↵
    1. Bertagna F,
    2. Bosio G,
    3. Caobelli F,
    4. Motta F,
    5. Biasiotto G,
    6. Giubbini R

    . Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis. Jpn J Radiol 2010;28:199–204.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Lehmann P,
    2. Buchtala S,
    3. Achajew N,
    4. Haerle P,
    5. Ehrenstein B,
    6. Lighvani H,
    7. et al.

    18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol 2011;30:37–42.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Soussan M,
    2. Nicolas P,
    3. Schramm C,
    4. Katsahian S,
    5. Pop G,
    6. Fain O,
    7. et al.

    Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine 2015;94:e622.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Lee YH,
    2. Choi SJ,
    3. Ji JD,
    4. Song GG

    . Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis: a meta-analysis. Z Rheumatol 2016;75:924–31.

    OpenUrl
15. 15.↵
    1. Dejaco C,
    2. Ramiro S,
    3. Duftner C,
    4. Besson FL,
    5. Bley TA,
    6. Blockmans D,
    7. et al.

    EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018;77:636–43.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. de Leeuw K,
    2. Bijl M,
    3. Jager PL

    . Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculitides. Clin Exp Rheumatol 2004;6 Suppl 36: S21–6.

    OpenUrl
17. 17.↵
    1. Stenova E,
    2. Mistec S,
    3. Povinec P

    . FDG-PET/CT in large-vessel vasculitis: its diagnostic and follow-up role. Rheumatol Int 2010;30:1111–14.

    OpenUrlPubMed
18. 18.↵
    1. Blockmans D,
    2. de Ceuninck L,
    3. Vanderschueren S,
    4. Knockaert D,
    5. Mortelmans L,
    6. Bobbaers H

    . Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131–7.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Quinn KA,
    2. Ahlman MA,
    3. Malayeri AA,
    4. Marko J,
    5. Civelek AC,
    6. Rosenblum JS,
    7. et al.

    Comparison of magnetic resonance angiography and (18)F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis 2018;77:1165–71.

    OpenUrl
20. 20.↵
    1. Duftner C,
    2. Dejaco C,
    3. Sepriano A,
    4. Falzon L,
    5. Schmidt WA,
    6. Ramiro S

    . Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open 2018;4:e000612.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Dellavedova L,
    2. Carletto M,
    3. Faggioli P,
    4. Sciascera A,
    5. Del Sole A,
    6. Mazzone A,
    7. et al.

    The prognostic value of baseline (18)F-FDG PET/CT in steroid-naive large-vessel vasculitis: introduction of volume-based parameters. Eur J Nucl Med Mol Imaging 2016;43:340–8.

    OpenUrl
22. 22.↵
    1. Nielsen BD,
    2. Gormsen LC,
    3. Hansen IT,
    4. Keller KK,
    5. Therkildsen P,
    6. Hauge EM

    . Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging 2018;45:1119–28.

    OpenUrl
23. 23.↵
    1. Hunder GG,
    2. Bloch DA,
    3. Michel BA,
    4. Stevens MB,
    5. Arend WP,
    6. Calabrese LH,
    7. et al.

    The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–8.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Arend WP,
    2. Michel BA,
    3. Bloch DA,
    4. Hunder GG,
    5. Calabrese LH,
    6. Edworthy SM,
    7. et al.

    The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129–34.

    OpenUrlPubMed
25. 25.↵
    1. Langford CA,
    2. Cuthbertson D,
    3. Ytterberg SR,
    4. Khalidi N,
    5. Monach PA,
    6. Carette S,
    7. et al;
    8. Vasculitis Clinical Research Consortium

    . A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 2017;69:837–45.

    OpenUrlCrossRef
26. 26.↵
    1. Tombetti E,
    2. Mason JC

    . Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology 2019;58:206–19.

    OpenUrl
27. 27.↵
    1. Merkel PA,
    2. Cuthbertson DD,
    3. Hellmich B,
    4. Hoffman GS,
    5. Jayne DR,
    6. Kallenberg CG,
    7. et al;
    8. Vasculitis Clinical Research Consortium

    . Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009;68:103–6.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Pepys MB,
    2. Hirschfield GM

    . C-reactive protein: a critical update. J Clin Invest 2003;111:1805–12.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Slart RH;
    2. Writing group; Reviewer group; Members of EANM Cardiovascular; Members of EANM Infection & Inflammation; Members of Committees, SNMMI Cardiovascular; Members of Council, PET Interest Group; Members of ASNC; EANM Committee Coordinator

    . FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 2018;45:1250–69.

    OpenUrl
30. 30.↵
    1. Muto G,
    2. Yamashita H,
    3. Takahashi Y,
    4. Miyata Y,
    5. Morooka M,
    6. Minamimoto R,
    7. et al.

    Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT. Rheumatol Int 2014;34:1545–54.

    OpenUrlCrossRefPubMed
31. 31.
    1. Otsuka H,
    2. Morita N,
    3. Yamashita K,
    4. Nishitani H

    . FDG-PET/CT for diagnosis and follow-up of vasculitis. J Med Invest 2007;54:345–9.

    OpenUrlCrossRefPubMed
32. 32.
    1. Bleeker-Rovers CP,
    2. Bredie SJ,
    3. van der Meer JW,
    4. Corstens FH,
    5. Oyen WJ

    . F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med 2003;61:323–9.

    OpenUrlPubMed
33. 33.
    1. Sager S,
    2. Yilmaz S,
    3. Ozhan M,
    4. Halac M,
    5. Ergul N,
    6. Ciftci H,
    7. et al.

    F-18 Fdg PET/CT findings of a patient with Takayasu arteritis before and after therapy. Mol Imaging Radionucl Ther 2012;21:32–4.

    OpenUrl
34. 34.
    1. Iwabu M,
    2. Yamamoto Y,
    3. Dobashi H,
    4. Kameda T,
    5. Kittaka K,
    6. Nishiyama Y

    . F-18 FDG PET findings of Takayasu arteritis before and after immunosuppressive therapy. Clin Nucl Med 2008;33:872–3.

    OpenUrlCrossRefPubMed
35. 35.
    1. Karunanithi S,
    2. Sharma P,
    3. Bal C,
    4. Kumar R

    . (18)F-FDG PET/CT for diagnosis and treatment response evaluation in large vessel vasculitis. Eur J Nucl Med Mol Imaging 2014;41:586–7.

    OpenUrlCrossRefPubMed
36. 36.
    1. Ceriani L,
    2. Oberson M,
    3. Marone C,
    4. Gallino A,
    5. Giovanella L

    . F-18 FDG PET-CT imaging in the care-management of a patient with pan-aortitis and coronary involvement. Clin Nucl Med 2007;32:562–4.

    OpenUrlPubMed
37. 37.↵
    1. Meller J,
    2. Strutz F,
    3. Siefker U,
    4. Scheel A,
    5. Sahlmann CO,
    6. Lehmann K,
    7. et al.

    Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003;30:730–6.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Park EH,
    2. Lee EY,
    3. Lee YJ,
    4. Ha YJ,
    5. Yoo WH,
    6. Choi BY,
    7. et al.

    Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. Rheumatol Int 2018;38:2233–42.

    OpenUrl
39. 39.↵
    1. Maleszewski JJ,
    2. Younge BR,
    3. Fritzlen JT,
    4. Hunder GG,
    5. Goronzy JJ,
    6. Warrington KJ,
    7. et al.

    Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol 2017;30:788–96.

    OpenUrl
40. 40.↵
    1. Lie JT

    . Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995;24:422–31.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Ostberg G

    . Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand Suppl 1972;533:135–59.

    OpenUrlPubMed
42. 42.↵
    1. Stone JH,
    2. Tuckwell K,
    3. Dimonaco S,
    4. Klearman M,
    5. Aringer M,
    6. Blockmans D,
    7. et al.

    Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–28.

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Villiger PM,
    2. Adler S,
    3. Kuchen S,
    4. Wermelinger F,
    5. Dan D,
    6. Fiege V,
    7. et al.

    Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921–7.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Reichenbach S,
    2. Adler S,
    3. Bonel H,
    4. Cullmann JL,
    5. Kuchen S,
    6. Butikofer L,
    7. et al.

    Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology 2018;57:982–6.

    OpenUrl
45. 45.↵
    1. Nakaoka Y,
    2. Isobe M,
    3. Takei S,
    4. Tanaka Y,
    5. Ishii T,
    6. Yokota S,
    7. et al.

    Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018;77:348–54.

    OpenUrlAbstract/FREE Full Text
46. 46.↵
    1. Molloy ES,
    2. Langford CA,
    3. Clark TM,
    4. Gota CE,
    5. Hoffman GS

    . Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567–9.

    OpenUrlAbstract/FREE Full Text
47. 47.↵
    1. Schmidt J,
    2. Kermani TA,
    3. Bacani AK,
    4. Crowson CS,
    5. Matteson EL,
    6. Warrington KJ

    . Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res 2012;64:1079–83.

    OpenUrl
48. 48.↵
    1. Hoffman GS,
    2. Cid MC,
    3. Rendt-Zagar KE,
    4. Merkel PA,
    5. Weyand CM,
    6. Stone JH,
    7. et al;
    8. Infliximab-GCA Study Group

    . Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Int Med 2007;146:621–30.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. Rosenbaum D,
    2. Millon A,
    3. Fayad ZA

    . Molecular imaging in atherosclerosis: FDG PET. Curr Atheroscler Rep 2012;14:429–37.

    OpenUrlCrossRefPubMed